Basilea Pharmaceutica has established an exclusive distribution and licensing agreement with Innoviva Specialty Therapeutics, a division of Innoviva (INVA), to market its hospital anti-MRSA antibiotic, Zevtera, also known as ceftobiprole, within the United States.
Under this agreement, Basilea will receive an initial payment of $4 million, alongside tiered royalties from net sales, ranging from the high teens to mid-twenties percentage. Furthermore, Basilea stands to earn up to $223 million in sales milestones. Innoviva Specialty Therapeutics will also source its Zevtera product supply directly from Basilea.
